Drug intelligence / Profile preview

dulaglutide + sulfonylureas

Development stage
Unknown
Lead developer
Eli Lilly
Modality
Recombinant Proteins and Enzymes, Small Molecules
Administration
Subcutaneous (dulaglutide), Oral (sulfonylureas)
01

Overview

Dulaglutide + sulfonylureas is a combination therapy used in adults with type 2 diabetes mellitus to improve glycemic control. **Dulaglutide** is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist administered once weekly by subcutaneous injection; it stimulates glucose-dependent insulin secretion, suppresses inappropriate glucagon secretion, and slows gastric emptying, resulting in reduced fasting and postprandial blood glucose levels. **Sulfonylureas** are small molecule oral antidiabetic drugs that act by stimulating pancreatic beta cells to increase insulin secretion, independent of plasma glucose concentration. The combination is often used where glycemic control is insufficient with either agent alone, and is recognized in guidelines for type 2 diabetes management. This combination is not a fixed single formulation but refers to concomitant use of separate medications from each class[3][7].

02

Targets

GLP1R (GLP-1R)KATP channel (ATP-sensitive potassium channel)

Beyond the preview

Go deeper on dulaglutide + sulfonylureas.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dulaglutide + sulfonylureas.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call